Table 2 Concomitant medication usage during the treatment period by baseline serum alkaline phosphatase quartiles
From: Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults
Variables* | Baseline serum alkaline phosphatase quartiles, IU/L | P value†| |||
|---|---|---|---|---|---|
Q1 (< 79) | Q2 (79- < 96) | Q3 (96- < 116) | Q4 (≥ 116) | ||
N | 3486 | 3623 | 3577 | 3707 | Â |
Antihypertensive drugs | |||||
 Calcium channel blockers | 2804 (80.4) | 2954 (81.5) | 2958 (82.7) | 3110 (83.9) |  < 0.001 |
 Diuretics | 2011 (57.7) | 2028 (56.0) | 1901 (53.1) | 1750 (47.2) |  < 0.001 |
Lipid-lowering drugs | 5 (0.1) | 3 (0.1) | 6 (0.2) | 5 (0.1) | 0.790 |
Antiplatelet drugs | 33 (0.9) | 35 (1.0) | 26 (0.7) | 17 (0.5) | 0.045 |